Know what’s really happening at
Waypoint Bio before you sign on.
- On the roadmap
- Cell Therapy
- Spatial Biology
- AI Drug Discovery
Waypoint Bio is building a next-generation cell therapy platform that fuses ultra-high-resolution spatial multi-omics with AI and high-throughput in vivo testing to tackle solid tumors — one of the hardest frontiers in oncology. Backed by top-tier investors and armed with a proprietary screening approach, the company is compressing the design-test-iterate cycle for engineered cell therapies.
How we do it.
Most "AI market intel" is a summarized crawl of press releases. This Altis research is built from our knowledge graph of sector expert calls, synthesized with public sources.
Waypoint Bio
- Total funding raised
- $34.5M
- Series A last round
- $20M
- Year founded
- 2021
- Company size
- 11-50
- Headquarters
- New York City, New York, United States
- Funding rounds completed
- 3
- Investor quality signal
- Top Tier Investors
Press reported
Altis Verified
What's in the report
Most "AI market intel" is a summarized crawl of press releases. This is what customers, competitors, and former employees actually told us.
Market Overview
Market structure, where the company sits, and growth drivers.
- market map
- Cell Therapy landscape
- Cell Therapy growth rate
- CAGR
Total Addressable Market
Bottom-up TAM / SAM / SOM.
- Waypoint Bio TAM
- Cell Therapy market size
- market opportunity
Company Overview
What the company does and how it operates.
- what does Waypoint Bio do
- Waypoint Bio product
- business model
Product / Go-to-Market
Product, GTM motion, ICP, and who buys.
- Waypoint Bio customers
- who uses Waypoint Bio
- Waypoint Bio ICP
- go-to-market
Competitive Dynamics
The Altis Market Map and the Altis Win-Rate Index.
- Waypoint Bio competitors
- Waypoint Bio alternatives
- who competes with Waypoint Bio
- Waypoint Bio win rate
Customer Signals
Retention, satisfaction, and win/loss signals.
- Waypoint Bio reviews
- Waypoint Bio NRR
- Waypoint Bio churn
- current customers
- switching costs
Investment Debates
Investment thesis, moat, bull/bear, and key risks.
- Waypoint Bio investment thesis
- Waypoint Bio moat
- bull case bear case
- Waypoint Bio risk factors
Monetization & Financials
Business model, revenue model, and unit economics.
- Waypoint Bio ARR
- Waypoint Bio revenue
- Waypoint Bio valuation
- unit economics
Team and culture
Founders, leadership, and org.
- Waypoint Bio founders
- Waypoint Bio CEO background
- leadership team
- headcount
Trusted by
Ready to see the full picture?
Profile based on structured company data, public funding records, and Altis platform signals.